Form 4 filings across 2 companies. Net figures count open-market buys and sales only. EDGAR profile ↗
Lifetime net: -$342K
Reported holding is the most recent post-transaction share count on a Table I row.
How quickly this filer reports. Section 16 allows two business days from the transaction.
All 6 filings we hold were filed within the two-business-day deadline.
Counted in business days from the transaction date, or the deemed execution date where the filing reports one, excluding weekends and federal holidays. How this is measured · All late filings
The 10 most recent Form 4 transactions.
| Sep 8 | CADL | Candel Therapeutics, Inc. | AGRANT◆ | 64,000 | — | — | — | Open the original filing on SEC.gov |
| Jun 5 | LGND | Ligand Pharmaceuticals INC | AGRANT◆ | 2,938 | — | — | — | Open the original filing on SEC.gov |
| Jun 5 | LGND | Ligand Pharmaceuticals INC | FTAX | 182 | $237.00 | $43.1K | -3.5% | Open the original filing on SEC.gov |
| Jun 5 | LGND | Ligand Pharmaceuticals INC | AGRANT | 836 | — | — | +18.8% | Open the original filing on SEC.gov |
| Sep 22, 2025 | LGND | Ligand Pharmaceuticals INC | FTAX | 115 | $170.77 | $19.6K | -2.5% | Open the original filing on SEC.gov |
| Jun 6, 2025 | LGND | Ligand Pharmaceuticals INC | AGRANT◆ | 5,783 | — | — | — | Open the original filing on SEC.gov |
| Jun 6, 2025 | LGND | Ligand Pharmaceuticals INC | FTAX | 188 | $105.99 | $19.9K | -4.0% | Open the original filing on SEC.gov |
| Jun 6, 2025 | LGND | Ligand Pharmaceuticals INC | AGRANT | 1,209 | — | — | +34.2% | Open the original filing on SEC.gov |